ZIVO Bioscience Retained Earnings (Accumulated Deficit) 2016-2024 | ZIVO

ZIVO Bioscience retained earnings (accumulated deficit) from 2016 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

ZIVO Bioscience Retained Earnings (Accumulated Deficit) 2016-2024 | ZIVO

ZIVO Bioscience retained earnings (accumulated deficit) from 2016 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$168.1B
Vertex Pharmaceuticals (VRTX)$119.2B
Regeneron Pharmaceuticals (REGN)$113.7B
Gilead Sciences (GILD)$102.4B
Bristol Myers Squibb (BMY)$101.3B
CSL (CSLLY)$95.4B
GSK (GSK)$84.1B
Alnylam Pharmaceuticals (ALNY)$35B
Argenex SE (ARGX)$32.8B
Biogen (BIIB)$27.5B
BioNTech SE (BNTX)$27.5B
Moderna (MRNA)$24.5B
BeiGene (BGNE)$20.1B
Illumina (ILMN)$20.1B
Genmab (GMAB)$15.8B
BioMarin Pharmaceutical (BMRN)$13.1B
Vaxcyte (PCVX)$12.7B
Exact Sciences (EXAS)$12.5B
Insmed (INSM)$12.5B
Incyte (INCY)$12.2B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.1B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.5B
Legend Biotech (LEGN)$7.9B
Intra-Cellular Therapies (ITCI)$7.9B
Repligen (RGEN)$7.8B
Exelixis (EXEL)$7.4B